IL6 and Obesity: Evidence synthesis across multiple RCTs shows that semaglutide reduces hsCRP by 12–20%, TNF-α by 15–40%, and IL-6 by 10–25%, independent of weight loss or glycemic effects, in patients with type 2 diabetes and obesity.